Please login to the form below
lenvatinib
This page shows the latest lenvatinib news and features for those working in and with pharma, biotech and healthcare.
Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
The US Food and Drug Administration (FDA) has cleared checkpoint inhibitor Keytruda (pembrolizumab) plus tyrosine kinase inhibitor (TKI) Lenvima (lenvatinib) for the treatment of patients with advanced endometrial cancer that is
Latest news
-
Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients
The new data, presented at the 2021 American Society of Clinical Oncology ( ASCO) annual meeting, comes from the CLEAR/KEYNOTE-581 study, which is evaluating Lenvima (lenvatinib) plus Keytruda (pembrolizumab) or
-
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer
In this study, checkpoint inhibitor Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and Lenvima plus everolimus were compared to Pfizer’s tyrosine kinase inhibitor (TKI) Sutent (sunitinib) for the first-line treatment of
-
Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer
The results, from the KEYNOTE-581/CLEAR trial, demonstrated that Keytruda (pembrolizumab) and Lenvima (lenvatinib) met the primary endpoint of improved progression-free survival (PFS) compared to Pfizer’s Sutent (sunitinib)
-
Roche’s Tecentriq/Avastin combo improves survival in liver cancer
Merck is testing Keytruda alongside partner Eisai’s kinase inhibitor Lenvima (lenvatinib) – already-approved for first-line HCC – in the Leap-002 trial, picking up a breakthrough designation from the FDA
-
Merck CFO: we’re not only about Keytruda
He said the performance of other cancer drugs like Lenvima (lenvatinib) and Lynparza (olaparib), revenue from which doubled in the quarter – as well as the vaccine portfolio headed by cervical cancer
Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer
Roche’s Tecentriq/Avastin combo improves survival in liver cancer
Merck CFO: we’re not only about Keytruda
More from news
Approximately 2 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
Eisai: Bucking the trend with R&D growth
The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small cell lung cancer, while lenvatinib is also in phase
Eisai: Bucking the trend with R&D growth
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- OPEN Health Acquires ARK
- Live Webinar: Artificial Intelligence for Improving Patient Outcomes & Operational Efficiency
- CHANGING FACES: UNDERSTANDING THE KEY CUSTOMER CONTACT POINTS WITHIN THE ICS LANDSCAPE
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- AstraZeneca chooses Ireland for $360m manufacturing site
- Building the perfect behaviour-change buffet
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- David Hunt launches independent agency The Considered
- Lucid Group celebrates a double win at Communiqué 2021
- Live Webinar: Driving Healthcare Decisions with Natural Language Processing
- US orders 1.4 million more doses of Regeneron antibody cocktail
PMHub
ROAD
ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
